ARS Pharmaceuticals, Inc (SPRY NASDAQ) stock market data APIs
$8.9085
-0.67(-7.5%)
as of November 7, 2025
Try our APIs with
free plan!
ARS Pharmaceuticals, Inc Financial Data Overview
Price chart is built with
Anychart
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California.
Prev. Close
8.9085
Open
8.2366
High
8.9085
Low
8.0581
52 wk Range
8.05-18.9
Market Cap
875 M
Shares Outstanding
98 826 K
Revenue
112 M
EPS
0
Beta
0.817
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with ARS Pharmaceuticals, Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ARS Pharmaceuticals, Inc data using free add-ons & libraries
Get ARS Pharmaceuticals, Inc Fundamental Data
ARS Pharmaceuticals, Inc Fundamental data includes:
- Net Revenue: 112 M
- EBITDA: -58 733 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-06
- EPS/Forecast: -0.4581
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ARS Pharmaceuticals, Inc News
New
Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates
Lipocine (LPCN) came out with a quarterly loss of $0.59 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.44 per share a year ago. These figures are adjus...
NewAmsterdam Pharma Company N.V. (NAMS) Reports Q3 Loss, Lags Revenue Estimates
NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.41 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $0.18 per share a year ago....
DraftKings, Flutter downgraded: Wall Street's top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...
ARS Pharma Launches Get neffy® on Us for Patients with Severe Allergic Reactions to Improve Access to neffy (epinephrine nasal spray)
ARS Pharmaceuticals, Inc. Offers no-hassle, free virtual visit with healthcare provider for patients to receive neffy for $0 co-pay if eligible with commercial insurance Program is available to elig...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
